Clinic Hours:

1:30pm – 6:30pm (Mon-Thu)

Clinic Number
Emergencies:

911

Medical Cannabis Information

Cannabis_sativa_Koehler_drawing

“Chronic pain has consistently been the most common patient-reported qualifying condition, accounting for 61.4 percent of the total patient-reported qualifying conditions, on average (ranging from 33.3 percent to 72.5 percent in the period 1999–2016). Multiple sclerosis spasticity symptoms is the second most common, followed by chemotherapy-induced nausea and vomiting, posttraumatic stress disorder, and cancer (exhibit 2).”

https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2018.05266

 

“Overall, in 2016, 84.6 percent of patient-reported qualifying conditions (chronic pain, chemotherapy-induced nausea and vomiting, and MS spasticity symptoms) were supported by conclusive or substantial evidence of therapeutic effectiveness, according to the 2017 National Academies report (data not shown).4 This percentage was quite consistent across the time frame of available registry data (mean: 87.1 percent; standard deviation: 6.2 percent). However, there are many other less well-supported qualifying conditions, including some for which there is either no or insufficient evidence for efficacy (such as hepatitis C and muscular dystrophy) “

 

“Of the conditions for which patients are licensed to use medical cannabis, 84.6 percent have either substantial or conclusive evidence of efficacy, according to the categories outlined in the 2017 National Academies report.4 Thus, we believe not only that it is inappropriate for cannabis to remain a Schedule I substance, but also that state and federal policy makers should begin evaluating evidence-based ways for safely integrating cannabis research and products into the health care system.33”

 

https://www.sciencedirect.com/science/article/abs/pii/S0376871613005243

 

“Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD”

“Those with high PTSD scores were more likely to use cannabis to improve sleep, and for coping reasons more generally, compared with those with low PTSD scores. Cannabis use frequency was greater among those with high PTSD scores who used for sleep promoting purposes compared with those with low PTSD scores or those who did not use for sleep promoting purposes.”

 

https://www.sciencedirect.com/science/article/pii/S1525505017300732

 

 

https://www.sciencedirect.com/science/article/pii/S1525505017300732

Medical Cannabis

“An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use “

“Author links open overlay panelAnastasia S.SuraevaLisaToddbMichael T.BowenaDavid J.AllsopaIain S.McGregoraCarolIrelandbNicholasLintzeriscd “

 

“The survey yielded 976 responses; with 60.1% of the overall sample involving adults with epilepsy, while the remaining were children with epilepsy (Table 1). Geographically, responses were from across Australia: New South Wales (38.5%), Queensland (22%), Victoria (15.2%), Western Australia (13.6%), and South Australia (4.5%), with the remainder forming 6.1%. Epilepsy syndrome of unknown type was the most frequently reported type of epilepsy across both children (41%) and adults (46%) with epilepsy (see Data S2). The second highest frequency syndrome type was structural brain abnormality (4.6%) in children with epilepsy, and temporal lobe epilepsy (5.6%) in adults with epilepsy.”

“Adults with epilepsy, but not parents of children with epilepsy, indicated that recreational use of cannabis had fortuitously assisted in managing seizures. No parent or guardian reported using cannabis products to manage their child’s other medical conditions. In contrast, adults with epilepsy indicated that cannabis assisted in managing other cognitive, neurological, physical, and/or mental health conditions. Interestingly, adults who had reported having pain (e.g. chronic pain, migraines) or other neurological condition in addition to epilepsy were more likely to have tried cannabis products. Sexton and colleagues’ survey indicated that pain was the most frequently reported condition for which medicinal cannabis was being used, and that cannabis users reported to experience substantial symptom relief [28].”  “M. Sexton, C. Cuttler, J.S. Finnell, L.K. Mischley

A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy

Cannabis Cannabinoid Res, 1 (1) (2016), pp. 131-138 “

‘https://onlinelibrary.wiley.com/doi/epdf/10.1111/epi.12631?src=getftr”

“Despite these issues, what is clear is that we cannot ignore that a significant proportion of children and adults with epilepsy are using cannabis-based products in Australia, and that a high proportion of these people are reporting considerable benefit to their condition. Furthermore, a substantial proportion of respondents also reported reducing their use of AEDs after commencing cannabis products. While this may be due to a reduced requirement for AEDs to manage their condition due to positive effects of the cannabis product, it is concerning if this medication change is undertaken without close medical supervision. Given their prevalence of use identified in the present study, this possibility highlights the growing need to educate key patient groups on cannabis-based products and, in particular, to encourage patients to ensure they seek medical advice before making any major changes to their treatment regimen. Fortunately, preliminary findings from clinical trials examining the safety and efficacy of CBD are promising [21], [22], particularly for those with treatment-resistant epilepsies, but also for those with treatment-responsive epilepsy seeking a better side effect profile relative to conventional AEDs. However, further studies are necessary to increase our knowledge of the efficacy, “interaction effects, and safety of CBD, and to explore the potential role of other cannabinoids, either alone or in combination, in the treatment of epilepsy.”

https://www.sciencedirect.com/science/article/pii/S1525505017300732

“ (21)  E.J. Hess, K.A. Moody, A.L. Geffrey, S.F. Pollack, L.A. Skirvin, P.L. Bruno, et al.

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

Epilepsia, 57 (10) (2016), pp. 1617-1624 “

“ (22) O. Devinsky, E. Marsh, D. Friedman, E. Thiele, L. Laux, J. Sullivan, et al.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

Lancet Neurol, 15 (3) (2016), pp. 270-278 “

 

____________________________________________________________________________________

Medical Cannabis in Cancer

 

https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21260